United States

People: Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

11:35am EDT
Change (% chg)

€-2.42 (-2.50%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Oschmann, Stefan 

Dr. Stefan Oschmann, Ph.D. is Chairman of Executive Board and Chief Executive Officer at Merck KGaA since April 30, 2015. He was Deputy Chief Executive Officer, Vice Chairman of the Executive Board of Merck KGaA . He currently serves as Head of Pharmaceuticals at the company since January 1, 2011. He is responsible for Europe, the United States (Pharmaceuticals), Canada, Latin and Central America, as well as Africa and Middle East. After earning a degree in Veterinary Medicine and a Doctorate from Ludwig-Maximilians-Universitaet Muenchen, he took on a position at the International Atomic Energy Agency IAEA. In 1989 he joined the American company Merck & Co. (outside North America: MSD – Merck Sharp & Dohme). Following various positions in Belgium, the Netherlands and Austria he was appointed Vice President of Central and Eastern Europe in 1998 and Vice President of Europe in 1999. Until 2005 he was also in charge of the German business of Merck & Co. In 2005 he moved to the headquarters of Merck & Co., taking on the role of Senior Vice President in charge of Worldwide Human Health Marketing. In 2006 he became Member of Senior Management and Corporate Officer, in charge of Merck & Co.’s business in Europe, the Middle East, Africa and Canada. As of 2009, Dr. Oschmann served as President of Emerging Markets for Merck & Co. Since January 10, 2011 he is Chairman of the Board at Merck Serono S.A.

Basic Compensation

Total Annual Compensation, EUR 6,020,000
Restricted Stock Awards, EUR 765,000
Long-Term Incentive Plans, EUR --
All Other, EUR --
Fiscal Year Total, EUR 6,785,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --